Literature DB >> 18087761

Anticitrulline peptide antibodies (CCP3) in leprosy sera: a negative association.

Luiz Sergio Guedes-Barbosa1, Cristovão Mangueira, Morton Scheinberg.   

Abstract

Anticyclic citrullinated peptide antibodies (anti-CCP) have been described almost exclusively in patients with rheumatoid arthritis. Recently, these autoantibodies have been found in patients with active tuberculosis. Leprosy is another mycobacterial disease where the presence of autoantibodies has been described by several authors. In this study, 64 patients with leprosy (32 paucibacillary and 32 multibacillary forms of the disease) were evaluated and only 2 patients were positive for the presence of anti-CCP. The low frequency of anti-CCP in leprosy sera demonstrated in our study illustrates the high specificity of anti-CCP for the diagnosis of rheumatoid arthritis.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18087761     DOI: 10.1007/s10067-007-0810-z

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  6 in total

1.  Positive anti-cyclic citrullinated proteins and rheumatoid factor during active lung tuberculosis.

Authors:  O Elkayam; R Segal; M Lidgi; D Caspi
Journal:  Ann Rheum Dis       Date:  2005-12-16       Impact factor: 19.103

2.  Autoantibodies in leprosy sera.

Authors:  L S Guedes Barbosa; B Gilbrut; Y Shoenfeld; M A Scheinberg
Journal:  Clin Rheumatol       Date:  1996-01       Impact factor: 2.980

3.  Anti-neutrophil cytoplasmic antibodies in leprosy.

Authors:  Fernando Luiz Barros Edington; Maria Olívia Amado Ramos Bacellar; Paulo Roberto Machado; Lúcio Barbosa; Eliana Reis; Mitermayer Reis; Mittermayer Barreto Santiago
Journal:  Clin Rheumatol       Date:  2006-03-30       Impact factor: 2.980

Review 4.  Anti-CCP antibody testing as a diagnostic and prognostic tool in rheumatoid arthritis.

Authors:  T B Niewold; M J Harrison; S A Paget
Journal:  QJM       Date:  2007-04

5.  Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis.

Authors:  Solbritt Rantapää-Dahlqvist; Ben A W de Jong; Ewa Berglin; Göran Hallmans; Göran Wadell; Hans Stenlund; Ulf Sundin; Walther J van Venrooij
Journal:  Arthritis Rheum       Date:  2003-10

6.  Increased incidence of cytoplasmic ANCA (cANCA) and other autoantibodies in leprosy patients from western India.

Authors:  Vandana Pradhan; S S Badakere; U Shankar Kumar
Journal:  Lepr Rev       Date:  2004-03       Impact factor: 0.537

  6 in total
  6 in total

1.  Anti-cyclic citrullinated peptide antibodies and rheumatoid factor sera titers in leprosy patients from Mexico.

Authors:  María G Zavala-Cerna; Mary Fafutis-Morris; Cecilia Guillen-Vargas; Mario Salazar-Páramo; Diana E García-Cruz; Carlos Riebeling; Arnulfo Nava
Journal:  Rheumatol Int       Date:  2011-11-15       Impact factor: 2.631

2.  Anti-cyclic citrulline peptide antibody in non-tuberculous mycobacteria sera: a negative association.

Authors:  Mi-Kyoung Lim; Tae Sun Shim; Dong-Hyuk Sheen; Dong-Jib Na; Sun Seek Min; Seung-Cheol Shim
Journal:  Clin Rheumatol       Date:  2010-01-06       Impact factor: 2.980

3.  Negative specificity for DSF70 in ANA positive leprosy sera.

Authors:  Sandra Lúcia Euzébio Ribeiro; Gabriel Pacifico Seabra Nunes; Henrique Euzébio Guedes de Freitas; Cristóvão Mangueira; Morton Aaron Scheinberg
Journal:  Clin Rheumatol       Date:  2019-07-05       Impact factor: 2.980

4.  Hansen's Disease and Rheumatoid Arthritis Crossover of Clinical Symptoms: A Case Series of 18 Patients in the United States.

Authors:  Sarah M Labuda; John S Schieffelin; Jeffrey G Shaffer; Barbara M Stryjewska
Journal:  Am J Trop Med Hyg       Date:  2017-10-19       Impact factor: 2.345

Review 5.  Antibodies against cyclic citrullinated peptides in infectious diseases--a systematic review.

Authors:  Isabella Lima; Mittermayer Santiago
Journal:  Clin Rheumatol       Date:  2010-08-05       Impact factor: 2.980

6.  Diagnostic utility of anti-cyclic citrullinated peptide antibodies for rheumatoid arthritis in patients with active lung tuberculosis.

Authors:  Shunsuke Mori; Hiromichi Naito; Sumire Ohtani; Tohru Yamanaka; Mineharu Sugimoto
Journal:  Clin Rheumatol       Date:  2008-11-11       Impact factor: 2.980

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.